CS199673B2 - Method of producing polypeptides - Google Patents

Method of producing polypeptides Download PDF

Info

Publication number
CS199673B2
CS199673B2 CS772980A CS298077A CS199673B2 CS 199673 B2 CS199673 B2 CS 199673B2 CS 772980 A CS772980 A CS 772980A CS 298077 A CS298077 A CS 298077A CS 199673 B2 CS199673 B2 CS 199673B2
Authority
CS
Czechoslovakia
Prior art keywords
tyr
pro
leu
arg
azgly
Prior art date
Application number
CS772980A
Other languages
Czech (cs)
English (en)
Inventor
Anand S Dutta
Barrington J Furr
Michael B Giles
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Priority to CS79207A priority Critical patent/CS199674B2/cs
Publication of CS199673B2 publication Critical patent/CS199673B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
CS772980A 1976-05-11 1977-05-05 Method of producing polypeptides CS199673B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS79207A CS199674B2 (cs) 1976-05-11 1979-01-09 Způsob výroby polypeptidů

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
CS199673B2 true CS199673B2 (en) 1980-07-31

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
CS772980A CS199673B2 (en) 1976-05-11 1977-05-05 Method of producing polypeptides

Country Status (27)

Country Link
US (1) US4100274A (de)
JP (1) JPS52136172A (de)
AT (2) AT379400B (de)
AU (1) AU508025B2 (de)
BE (1) BE854467A (de)
BG (1) BG60740B2 (de)
CA (1) CA1101844A (de)
CH (2) CH627151A5 (de)
CS (1) CS199673B2 (de)
DD (1) DD136738A5 (de)
DE (1) DE2720245C2 (de)
DK (1) DK149596C (de)
ES (1) ES458691A1 (de)
FI (1) FI64139C (de)
FR (1) FR2351092A1 (de)
GB (1) GB1524747A (de)
HU (1) HU179990B (de)
IE (1) IE44426B1 (de)
IL (1) IL52014A (de)
NL (2) NL191793C (de)
NO (2) NO147304C (de)
NZ (1) NZ183931A (de)
PL (2) PL108860B1 (de)
SE (2) SE437837B (de)
SU (1) SU910116A3 (de)
YU (1) YU40672B (de)
ZA (1) ZA772433B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (de) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
CA2063378A1 (en) * 1989-07-07 1991-01-08 Fernand Labrie Androgen derivatives for use in the inhibition of sex steroid activity
WO1991000733A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Method of treatment of androgen-related diseases
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
SK140494A3 (en) * 1992-05-21 1995-07-11 Endorecherche Inc Inhibitors of testosterone 5-alpha-reductase activity
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
EP1008656A4 (de) * 1996-06-13 2000-09-20 Itoham Foods Inc Verfahren zur herstellung von lh-rh derivaten
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
NZ527692A (en) 2001-02-19 2005-05-27 Novartis Ag Cancer treatment
MXPA03010401A (es) 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
EP1444988A4 (de) 2001-11-13 2007-04-25 Takeda Pharmaceutical Krebsmittel
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2810477C (en) 2002-12-13 2013-09-17 Durect Corporation Oral drug delivery system
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
CA2560162C (en) 2004-04-07 2013-05-21 Novartis Ag Inhibitors of iap
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2113513B1 (de) * 2004-06-25 2016-05-18 Takeda Pharmaceutical Company Limited Metastinderivate und deren Verwendung
SI2767292T1 (sl) * 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006119388A2 (en) 2005-05-03 2006-11-09 Novetide, Ltd. Methods for the production of peptide having a c-terminal amide
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20080255149A1 (en) 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP2026800A1 (de) 2006-05-09 2009-02-25 Novartis AG Kombination aus einem eisenchelatbildner und einem anti-neoplastischen mittel und ihre verwendung
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
PE20090519A1 (es) 2007-02-15 2009-05-29 Novartis Ag Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
EP3326621A1 (de) 2007-12-06 2018-05-30 Durect Corporation Orale arzneimitteldosierformen
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MX2011005667A (es) * 2008-11-28 2011-06-16 Novartis Ag Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor.
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
CN102648188A (zh) 2009-12-08 2012-08-22 诺瓦提斯公司 杂环磺酰胺衍生物
AU2012265844A1 (en) 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
BR112012032189B1 (pt) 2010-06-16 2020-11-03 Endorecherche, Inc usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
CN103608349A (zh) 2011-06-27 2014-02-26 诺瓦提斯公司 四氢-吡啶并-嘧啶衍生物的固体形式和盐
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP2785717B1 (de) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidinverbindungen
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
KR101656592B1 (ko) 2011-12-22 2016-09-23 노파르티스 아게 디히드로-벤조-옥사진 및 디히드로-피리도-옥사진 유도체
JP2015503519A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
CN104136428A (zh) 2011-12-23 2014-11-05 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
EP2855483B1 (de) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinonverbindungen
CN104582732A (zh) 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
EA201590372A1 (ru) 2012-08-13 2015-05-29 Новартис Аг Бициклические гетероарилциклоалкилдиаминовые производные в качестве ингибиторов тирозинкиназ селезенки (syk)
AP2015008389A0 (en) 2012-10-02 2015-04-30 Epitherapeutics Aps Inhibitors of histone demethylases
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
AP2015008676A0 (en) 2013-02-27 2015-08-31 Epitherapeutics Aps Inhibitors of histone demethylases
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
MY184292A (en) 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
MX2016009226A (es) 2014-01-15 2016-10-05 Novartis Ag Combinaciones farmaceuticas.
EP3327006B1 (de) 2014-03-28 2020-05-20 Calitor Sciences, LLC Substituierte heteroarylverbindungen und verfahren zur verwendung
CA2943824A1 (en) 2014-03-31 2015-10-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
CN107074807A (zh) 2014-08-27 2017-08-18 吉利德科学公司 用于抑制组蛋白脱甲基酶的组合物和方法
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
JP7450541B2 (ja) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換アミノピリミジン化合物及び使用方法
WO2021059266A1 (en) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
EP4058465A1 (de) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4-antagonistenpeptide
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (de) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
US4100274A (en) 1978-07-11
DK207977A (da) 1977-11-12
DE2720245A1 (de) 1977-11-24
PL108860B1 (en) 1980-05-31
NO771644L (no) 1977-11-14
NO149586C (no) 1984-05-16
DK149596C (da) 1987-01-05
AU2468177A (en) 1978-11-02
FI64139B (fi) 1983-06-30
AT365562B (de) 1982-01-25
DK149596B (da) 1986-08-04
DE2720245C2 (de) 1986-09-25
DD136738A5 (de) 1979-07-25
SE437837B (sv) 1985-03-18
FR2351092B1 (de) 1980-02-22
NO149586B (no) 1984-02-06
YU117277A (en) 1983-02-28
NO822984L (no) 1977-11-14
NL7705130A (nl) 1977-11-15
ATA335877A (de) 1985-05-15
BG60740B2 (bg) 1996-01-31
CH629475A5 (de) 1982-04-30
YU40672B (en) 1986-04-30
NZ183931A (en) 1979-03-16
PL197889A1 (pl) 1978-02-13
NL970002I1 (nl) 1997-03-03
NO147304B (no) 1982-12-06
FR2351092A1 (fr) 1977-12-09
SE437993B (sv) 1985-03-25
FI64139C (fi) 1983-10-10
IE44426L (en) 1977-11-11
NO147304C (no) 1983-03-16
AU508025B2 (en) 1980-03-06
IL52014A (en) 1979-11-30
JPS6113480B2 (de) 1986-04-14
CA1101844A (en) 1981-05-26
JPS52136172A (en) 1977-11-14
FI771480A (de) 1977-11-12
PL104362B1 (pl) 1979-08-31
SE7705432L (sv) 1977-11-12
ZA772433B (en) 1978-03-29
GB1524747A (en) 1978-09-13
SU910116A3 (ru) 1982-02-28
NL191793B (nl) 1996-04-01
AT379400B (de) 1985-12-27
HU179990B (en) 1983-01-28
CH627151A5 (de) 1981-12-31
IE44426B1 (en) 1981-11-18
IL52014A0 (en) 1977-07-31
NL970002I2 (nl) 1997-05-01
BE854467A (fr) 1977-11-10
SE8007763L (sv) 1980-11-05
ATA217979A (de) 1981-06-15
ES458691A1 (es) 1978-08-16
NL191793C (nl) 1996-08-02

Similar Documents

Publication Publication Date Title
CS199673B2 (en) Method of producing polypeptides
US3853837A (en) Novel nonapeptide amide analogs of luteinizing hormone releasing factor
US4024248A (en) Peptides having LH-RH/FSH-RH activity
IE902740A1 (en) Lhrh analogs
HU185535B (en) Process for preparing new gonadoliberin derivatives
HU186749B (en) Process for preparing new, biologically active peptides
US4003884A (en) Peptides having LH-RH/FSH-RH activity
HU200481B (en) Process for producing new peptides having natural lh-rh antagonistic activity and pharmaceutical compositions comprising same
US4124703A (en) Luliberin analogs
US4647553A (en) Gonadoliberin derivatives and process for the preparation thereof
US3862927A (en) Process for preparation of vasoactive intestinal peptide
SE461042B (sv) Peptider med tillvaextbefraemjande aktivitet jaemte veterinaera kompositioner innehaallande naemnda peptider
HU194913B (en) Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds
US3801561A (en) Derivatives of salmon thyrocalcitonin
US3850904A (en) Psychopharmacologically active d-glu or d-his containing peptides
Van Nispen et al. INVESTIGATION OF THE ROLE OF TRYPTOPHAN IN α‐MSH*: Replacement by L‐Pentamethylphenylalanine and L‐Phenylalanine
GB2130590A (en) Peptides
US3873510A (en) Peptides of ACTH activity containing {60 -aminooxy carboxylic acid on the N-terminal moiety, and a process for the preparation thereof
HU187503B (en) Process for preparing gonadoliberine derivatives containing beta-aspartyl group
GB2109796A (en) Anorexigenic tripeptides, process for the preparation thereof and pharmaceutical compositions containing them
US3400118A (en) Intermediates in the preparation of secretin
KiSFALUDY et al. Pentagastrin Analogs Containing α-Aminooxy Acids, I Synthesis of Analogs Substituted at the N-Terminus
US3417072A (en) Intermediates in the synthesis of secretin
US3812091A (en) D-analogs of secretin
US3767639A (en) Process for the preparation of secretin